Insider · CIK 0001514063
Suren G Dutia
Files at CTXR (Citius Pharmaceuticals, Inc.), CTOR (CITIUS ONCOLOGY, INC.). First filing -, latest -.
Suren G Dutia files SEC Form 4 as director at CTXR (Citius Pharmaceuticals, Inc.), and also at CTOR (CITIUS ONCOLOGY, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Suren G Dutia has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 22, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Dec 1, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 300,000 | Sep 23, 2025 |
| Dec 12, 2024 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 16, 2024 |
| Nov 7, 2024 | CTXR Citius Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Purchase Common Stock)derivative | +125,000 | $0.00 | $0 | 125,000 | Nov 12, 2024 |
Questions about Suren G Dutia
Answered from the filings on this page, as of the latest one.
Is Suren G Dutia buying or selling?
Suren G Dutia has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Suren G Dutia's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Suren G Dutia has 0.
Where does Suren G Dutia file Form 4?
Suren G Dutia has filed Form 4 at CTXR (Citius Pharmaceuticals, Inc.); CTOR (CITIUS ONCOLOGY, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.